Management of mitochondrial-related heart disease relies on multidisciplinary care and symptom control, as targeted gene-editing therapies are limited.

NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition pore (mPTP), acting through a novel undisclosed ...

Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat – a once-daily, oral investigational medicine – as a treatment for the rare ...

Thiogenesis Therapeutics Corp ( ($TSE:TTI) ) just unveiled an update. Thiogenesis Therapeutics announced that CEO Patrice Rioux will present ...

Despite being renowned as the “powerhouse of the cell,” mitochondria can also be a source of heartache for those living with mitochondrial disease—especially when planning to have children. Because ...